Table 1

Demographics, laboratory, and clinical characteristics of subjects

Controls

(n = 83)

SLE

(n = 108)


Demographics

Female (%)

93

94

Mean age (years)

36

38

Race/ethnicity (%)

African-American

35

36

White

32

40

Others

33

24

Disease duration (years)

-

12.1 ± 0.7

ACR criteria (mean)

-

6.2 ± 0.2

Serum markers

C3 (mg/dL)

123.4 ± 5.7

95.4 ± 5.5

C4 (mg/dL)

25.7 ± 3.5

19.7 ± 1.5

hsCRP (mg/dL)

1.4 [1.1-4.4]

5.7 [4.1-7.1]

SLE manifestationsa(%)

CNS

-

18

Skin

-

63

Joint

-

84

Serositis

-

34

Anti-dsDNA

-

61

Anti-Sm

-

45

Anti-phospholipid

-

50

Medication use (%)

Prednisone

-

51

Mean dose (mg/day)

15.5

Antimalarials

-

70

Cytotoxic agentsb

-

21

Statins

-

18

ACE inhibitors

-

48


aPresence of specific manifestations at any point during the course of disease.

bCytotoxic agents included cyclophosphamide, mofetil mycophenolate, azathioprine, and methotrexate.

ACR, American College of Rheumatology; C3, C4, complement 3 and complement 4; hs-CRP, high sensitivity C-reactive protein; SLE, systemic lupus erythematosus.

Li et al. Arthritis Research & Therapy 2010 12:R90   doi:10.1186/ar3017

Open Data